<?xml version="1.0" encoding="utf-8"?>
<journal>
<title>International Journal of Radiation Research</title>
<title_fa>نشریه پرتو پژوه</title_fa>
<short_title>Int J Radiat Res</short_title>
<subject>Basic Sciences</subject>
<web_url>http://ijrr.com</web_url>
<journal_hbi_system_id>79</journal_hbi_system_id>
<journal_hbi_system_user>journal79</journal_hbi_system_user>
<journal_id_issn>2322-3243</journal_id_issn>
<journal_id_issn_online>2345-4229</journal_id_issn_online>
<journal_id_pii></journal_id_pii>
<journal_id_doi>10.61882/ijrr</journal_id_doi>
<journal_id_iranmedex></journal_id_iranmedex>
<journal_id_magiran></journal_id_magiran>
<journal_id_sid></journal_id_sid>
<journal_id_nlai></journal_id_nlai>
<journal_id_science></journal_id_science>
<language>en</language>
<pubdate>
	<type>jalali</type>
	<year>1404</year>
	<month>10</month>
	<day>1</day>
</pubdate>
<pubdate>
	<type>gregorian</type>
	<year>2026</year>
	<month>1</month>
	<day>1</day>
</pubdate>
<volume>24</volume>
<number>1</number>
<publish_type>online</publish_type>
<publish_edition>1</publish_edition>
<article_type>fulltext</article_type>
<articleset>
	<article>


	<language>en</language>
	<article_id_doi></article_id_doi>
	<title_fa></title_fa>
	<title>Study on quantitative parameters of intravoxel incoherent motion-diffusion weighted imaging to evaluate the treatment effect of transcatheter arterial chemoembolization combined with 3-dimensional conformal radiation therapy in patients with primary liver cancer</title>
	<subject_fa>Radiation Biology</subject_fa>
	<subject>Radiation Biology</subject>
	<content_type_fa>تحقيق بديع</content_type_fa>
	<content_type>Original Research</content_type>
	<abstract_fa></abstract_fa>
	<abstract>&lt;div style=&quot;text-align: justify;&quot;&gt;&lt;span style=&quot;font-size:10pt&quot;&gt;&lt;span style=&quot;text-justify:newspaper&quot;&gt;&lt;span style=&quot;text-kashida-space:50%&quot;&gt;&lt;span style=&quot;line-height:119%&quot;&gt;&lt;span style=&quot;font-family:Calibri&quot;&gt;&lt;span style=&quot;color:black&quot;&gt;&lt;span lang=&quot;en-US&quot; style=&quot;font-size:9.0pt&quot;&gt;&lt;span style=&quot;font-family:Calibri&quot;&gt;&lt;span style=&quot;color:#1f497d&quot;&gt;&lt;span style=&quot;font-style:italic&quot;&gt;&lt;span style=&quot;font-weight:bold&quot;&gt;&lt;span style=&quot;language:en-US&quot;&gt;Background:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; &lt;span lang=&quot;en-GB&quot; style=&quot;font-size:9.0pt&quot;&gt;&lt;span style=&quot;font-family:Calibri&quot;&gt;&lt;span style=&quot;color:black&quot;&gt;&lt;span style=&quot;language:en-GB&quot;&gt;To observe the effect of quantitative parameters of intravoxel incoherent motion-diffusion weighted imaging (IVIM-DWI) in the evaluation of transcatheter arterial chemoembolization (TACE) combined with 3-dimensional conformal radiation therapy (3D-CRT) treatment effect. &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span lang=&quot;en-GB&quot; style=&quot;font-size:9.0pt&quot;&gt;&lt;span style=&quot;font-family:Calibri&quot;&gt;&lt;span style=&quot;color:#1f497d&quot;&gt;&lt;span style=&quot;font-style:italic&quot;&gt;&lt;span style=&quot;font-weight:bold&quot;&gt;&lt;span style=&quot;language:en-GB&quot;&gt;Materials and Methods: &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span lang=&quot;en-GB&quot; style=&quot;font-size:9.0pt&quot;&gt;&lt;span style=&quot;font-family:Calibri&quot;&gt;&lt;span style=&quot;color:black&quot;&gt;&lt;span style=&quot;language:en-GB&quot;&gt;Research subjects were selected from 80 cases of patients with primary liver cancer (PLC) from May 2021 to October 2022. According to the judgment criteria of treatment effect of solid tumors, the patients were divided into complete remission (CR)/partial remission (PR) group (n=37) and stable disease (SD)/progressive disease (PD) group (n=43) after TACE combined with 3D-CRT treatment. The quantitative parameters of IVIM-DWI [F value, D* value, D value and apparent diffusion coefficient (ADC) value] in the two groups were compared. &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span lang=&quot;en-GB&quot; style=&quot;font-size:9.0pt&quot;&gt;&lt;span style=&quot;font-family:Calibri&quot;&gt;&lt;span style=&quot;color:#1f497d&quot;&gt;&lt;span style=&quot;font-style:italic&quot;&gt;&lt;span style=&quot;font-weight:bold&quot;&gt;&lt;span style=&quot;language:en-GB&quot;&gt;Results: &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span lang=&quot;en-GB&quot; style=&quot;font-size:9.0pt&quot;&gt;&lt;span style=&quot;font-family:Calibri&quot;&gt;&lt;span style=&quot;color:black&quot;&gt;&lt;span style=&quot;language:en-GB&quot;&gt;The value of D*, F, D and ADC of IVIM-DWI quantitative parameters in the SD/PD group were all higher&#8204; (P&lt;0.05). The receiver operating characteristic (ROC) curve indicated that the area under curve (AUC) of the value of D*, F, D and ADC in IVIM-DWI quantitative parameters of patients with PLC to predict the effect of TACE combined with 3D-CRT in patients were 0.827, 0.777, 0.827, 0.863 and 0.923, and the AUC of the combination prediction was the largest. The sensitivity and specificity of combined prediction were 92.3% and 81.1% (Youden index 0.896), respectively. &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span lang=&quot;en-GB&quot; style=&quot;font-size:9.0pt&quot;&gt;&lt;span style=&quot;font-family:Calibri&quot;&gt;&lt;span style=&quot;color:#1f497d&quot;&gt;&lt;span style=&quot;font-style:italic&quot;&gt;&lt;span style=&quot;font-weight:bold&quot;&gt;&lt;span style=&quot;language:en-GB&quot;&gt;Conclusion: &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span lang=&quot;en-GB&quot; style=&quot;font-size:9.0pt&quot;&gt;&lt;span style=&quot;font-family:Calibri&quot;&gt;&lt;span style=&quot;color:black&quot;&gt;&lt;span style=&quot;language:en-GB&quot;&gt;The value of D*, F, D and ADC in IVIM-DWI quantitative parameters are feasible to evaluate the treatment effect of TACE combined with 3D-CRT in patients with PLC.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;</abstract>
	<keyword_fa></keyword_fa>
	<keyword>Hepatocellular carcinomas, multiparametric magnetic resonance   imaging, radiotherapy, chemoembolization therapeutic, ROC Curve.</keyword>
	<start_page>97</start_page>
	<end_page>102</end_page>
	<web_url>http://ijrr.com/browse.php?a_code=A-10-1-1461&amp;slc_lang=en&amp;sid=1</web_url>


<author_list>
	<author>
	<first_name>Z. </first_name>
	<middle_name></middle_name>
	<last_name>Wu</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email></email>
	<code>7900319475328460032814</code>
	<orcid>7900319475328460032814</orcid>
	<coreauthor>No</coreauthor>
	<affiliation>Department of Radiology, The Second People's Hospital of Hunan Province, Changsha, Hunan, China</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


	<author>
	<first_name>Y. </first_name>
	<middle_name></middle_name>
	<last_name>Pang</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email></email>
	<code>7900319475328460032815</code>
	<orcid>7900319475328460032815</orcid>
	<coreauthor>No</coreauthor>
	<affiliation>Department of Radiology, The Second People's Hospital of Hunan Province, Changsha, Hunan, China</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


	<author>
	<first_name>J. </first_name>
	<middle_name></middle_name>
	<last_name>Wang</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email></email>
	<code>7900319475328460032816</code>
	<orcid>7900319475328460032816</orcid>
	<coreauthor>No</coreauthor>
	<affiliation>Department of Radiology, The Second People's Hospital of Hunan Province, Changsha, Hunan, China</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


	<author>
	<first_name>P. </first_name>
	<middle_name></middle_name>
	<last_name>Gao</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email></email>
	<code>7900319475328460032817</code>
	<orcid>7900319475328460032817</orcid>
	<coreauthor>No</coreauthor>
	<affiliation>Department of Interventional Medicine, The Second People's Hospital of Hunan Province, Changsha, Hunan, China</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


	<author>
	<first_name>W. </first_name>
	<middle_name></middle_name>
	<last_name>Yin</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email></email>
	<code>7900319475328460032818</code>
	<orcid>7900319475328460032818</orcid>
	<coreauthor>No</coreauthor>
	<affiliation>Department of Oncology, The Second People's Hospital of Hunan Province, Changsha, Hunan, China</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


	<author>
	<first_name>Y.</first_name>
	<middle_name></middle_name>
	<last_name>Xia</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email>yizherenx5555@163.com </email>
	<code>7900319475328460032819</code>
	<orcid>7900319475328460032819</orcid>
	<coreauthor>Yes
</coreauthor>
	<affiliation>Medical Imaging Center, Jiujiang NO.1 People's Hospital, Jiujiang, Jiangxi, China</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


</author_list>


	</article>
</articleset>
</journal>
